.

SweetSpot hits the… Oh. Um. Well, it secures seed funding for diabetes data services

When it comes to technology, health care, ironically, tends to fall closer to the rusting edge than the bleeding edge. But that shortcoming is a boon for startups that can figure out how to use today’s technology to solve health care’s problems—both for providers and patients.

One such company is Portland-based SweetSpot, a startup that seeks to help diabetics and their care givers better manage health information by providing a central resource for blood glucose tracking and reporting. And today, Sweetspot is one step closer that helping fix its own corner of health care, thanks to a round of seed funding.

While the terms and amounts were not released, the investors have impressive pedigrees. They include Dick Sass, Bill Trenchard, and Alan Lefkof.

“It’s gratifying to find investors who believe in what you are doing, especially in today’s environment. We ended up with a mix of Portland and Silicon Valley-based entrepreneurs I could not have more respect for,” said SweetSpot Diabetes CEO Christopher Logan, formerly of ccSync, in a press release.

SweetSpot Diabetes is a health data company focused on improving the use of data in the treatment of diabetes. SweetSpot specializes in turning raw output from patient devices into powerful information for researchers, health care providers and patients. In clinics or from home SweetSpot performs all data extraction and analysis, relieving frustration with multiple interfaces, drivers and data formats.

For more information, visit SweetSpot.

  1. […] SweetSpot hits the… Oh. Um. Well, it secures seed funding for diabetes data services (3) […]

  2. […] SweetSpot hits the… Oh. Um. Well, it secures seed funding for diabetes data services (2) […]

  3. […] SweetSpot hits the… Oh. Um. Well, it secures seed funding for diabetes data services (1) […]

  4. Huge congrats Chris and team!

    Loved the SweetSpot demo and concept. Good luck getting out into the market and making a big wave.

Comments are closed.